Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CET

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
12:36a Pharma execs weigh in on possible changes under Trump
11/30DJValeant's Discussions to Sell Salix to Takeda Have Broken Down
11/23 Lilly's drug for Alzheimer's fails big trial; shares drop
11/15 Teva trims 2016 outlook on drug launch delays
11/15DJTEVA PHARMACEUTICAL INDUSTRIES : Revenue Rises on Allergan Deal -- Update
11/04 Drugmakers under fire for possible U.S. price fixing
11/02 Allergan CEO takes blame for big miss on quarterly earnings
11/02DJU.S. HOT STOCKS : Hot Stocks to Watch
11/01DJValeant, Saddled With Debt, in Talks to Sell Big Drug Line
11/01DJPFIZER : Cuts Outlook, Ends Development of Cholesterol Drug
More news
Sector news : Pharmaceuticals - NEC
12:36a Pharma execs weigh in on possible changes under Trump
12:24aDJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ($)
Sales 2016 14 490 M
EBIT 2016 7 214 M
Net income 2016 -
Debt 2016 21 545 M
Yield 2016 0,25%
P/E ratio 2016 -
P/E ratio 2017 67,27
EV / Sales 2016 6,41x
EV / Sales 2017 5,67x
Capitalization 71 404 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 263 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC71 404
JOHNSON & JOHNSON8.43%303 013
PFIZER INC.-2.54%190 910
ROCHE HOLDING LTD.-17.98%189 262
NOVARTIS AG-19.07%177 818
MERCK & CO., INC.15.85%167 524
More Results